Podcasts about promising

Podcast growth professionals. If you're presently hosting a podcast, these monetization experts have sent you emails and messages through LinkedIn. Can you trust them? Are they the real deal? Who is footing the bill?

Preview: Dr. Henry Miller celebrates vaccines for dramatically increasing longevity and eradicating diseases like polio. He notes the success of COVID-19 shots and criticizes the NIH for defunding promising mRNA cancer research. 1919

Podcast growth professionals. If you're presently hosting a podcast, these monetization experts have sent you emails and messages through LinkedIn. Can you trust them? Are they the real deal? Who is footing the bill?Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-like-it-s-live--4113802/support.

On Today's Show: First world problems: "tech is trauma" and stepfather phone problems + Ozempic problems____________Marty Lancton, President of the Houston Professional Fire Fighters Association and candidate for Harris County Judge, is calling for a return to basics. He says it's time to stop focusing on divisive social issues and start delivering real results. Harris County residents, he emphasizes, deserve common sense leadership, accountability, and solutions—not excuses.Lancton vows to end the mismanagement that has plagued county government and to work with state leaders instead of wasting time and taxpayer money on lawsuits.Follow Lancton: lanctonforharriscounty.com_____________For years, the Left has gone out of their way to smear conservatives—and after Charlie Kirk's murder, they have doubled down. Only the Left could mock a murdered man, then appear on TV lying about the shooter and still claim to be the victims for losing their jobs over their comments.The Charlie Kirk Memorial itself was extraordinary. Over 100 million people tuned in online—not even counting broadcast audiences. The event brought together voices like Tucker Carlson and Stephen Miller, who don't always agree on issues like Israel, yet stood united in honoring Charlie. Even people who weren't fans before are now discovering his work and finding themselves in agreement.Meanwhile, Jimmy Kimmel returns to late night as if nothing happened—still refusing to apologize for his disgraceful comments about Charlie.____________________Let's discuss the Jasmin Crockett / Laura Loomer feud, and how Crockett thinks her constituents are useful idiots. She code switches according to her audience.On the Isiah Factor this week, Representative Ron Reynolds said that MAGA is revving up the rhetoric surrounding the Charlie Kirk assassination.Gavin Newsom's foot-in-mouth tweet about Kristi Noem that could have been better stated.And finally let's talk about the ICE facility in Dallas that was shot up by someone who wrote "anti-ICE" on the bullets. Wonder which side of the aisle they're on.____________________Today's sponsor is New Frontier Creative Media. Angela proudly uses New Frontier to edit her videos and manage her social media profiles. They also created her logo and built her website. newfrontiercreative.com | 409-781-4164Mention Angela and Receive 15% Off Any Service.________________Try Out These Products That Angela Uses:Get $15 Off of First Order with Froya Organics:froyaorganics.com/angelaboxshowGet 10% Off Your Purchase of Angel Lift: angellift.com/angelaboxshowAll content: AngelasSoapBox.com Twitter/Instagram: @theboxthatroxx Facebook: @AngelaBoxShow Truth Social: @AngelaBox iHeart: https://www.iheart.com/podcast/269-the-angela-box-show-88287019/ Apple: https://podcasts.apple.com/us/podcast/the-angela-box-show/id1591500325 Spotify: https://open.spotify.com/show/1J5hSQA0LxkyZLKq9jdsbf?si=203fa05c97204ea8 Rumble: https://rumble.com/AngelaBoxShow Bitchute: https://www.bitchute.com/AngelaBoxShow YouTube: https://www.youtube.com/@AngelaBoxShow TikTok: https://www.tiktok.com/@theangelaboxshow

This episode will expire in 24 hours! Missed an episode? Pick it back up anytime! Want the back catalog? Become a supporter on Patreon! patreon.com/mercuryradio More info about ARTC And Mercury at artc.org/mercury  Follow us on Bluesky @mercury870

Podcast growth professionals. If you're presently hosting a podcast, these monetization experts have sent you emails and messages through LinkedIn. Can you trust them? Are they the real deal? Who is footing the bill?Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid-stage obesity study for strategic reasons, Harmony has failed a pivotal trial for fragile X syndrome, and the FDA has released guidance to streamline the development of cell and gene therapies. Overall, Immuneering's drug shows potential in improving survival rates for pancreatic cancer patients, with further trials planned for the future.

The latest developments surrounding Ozempic and weight loss continue to generate major interest and headlines, especially with new research and high-profile figures like Oprah Winfrey sharing personal experiences. In the past week, new clinical trial data and ongoing cultural conversations have kept this topic at the forefront.Researchers have revealed that a daily pill version of semaglutide—the active ingredient in Ozempic—can deliver weight loss results comparable to injectables. According to reporting in The New England Journal of Medicine, participants in a 64-week trial who took oral semaglutide lost over 16 percent of their baseline body weight, while those on a placebo lost just 2.7 percent. More than a third of those on the Ozempic pill achieved at least a 20 percent weight reduction. These findings indicate that more convenient alternatives to weekly injections could soon be available for people seeking medical weight management. Cardiovascular risk factors and physical function also improved among those taking the new pill, further supporting its potential for broader approval later in the year.While Ozempic is widely recognized for its effect on appetite—helping users feel full sooner and eat less—the discussion about its effectiveness versus other weight loss methods also remains active. Recent clinical data suggest that surgery still leads to substantially greater average weight loss over time. At New York University, researchers found that patients receiving bariatric surgery lost about 25 percent of their body weight over two years, compared to approximately 5 percent for those sticking with GLP-1 agonists like Ozempic. Factors such as medication adherence and long-term commitment play a massive role in these outcomes. In fact, studies estimate that up to 70 percent of patients may discontinue their weight loss medications within the first year. Experts say this underscores the importance of treating obesity as a chronic and complex disease rather than seeking a one-size-fits-all solution.Oprah Winfrey continues to shape the public conversation about medical weight loss, drawing both criticism and admiration for her openness and candor this week. On her podcast, Oprah confirmed she has used a GLP-1 agonist—though not specifying Ozempic by name—to quiet her mind's “food noise” and help manage her weight. She explained that the drug's effect of mimicking a natural hormone made her realize many people are not waging an internal battle with cravings but simply respond to true hunger and fullness cues. For decades, Oprah says she blamed herself for her struggles, thinking thinness was a matter of willpower or discipline, only to learn that biological predisposition can override even the strongest effort.As she approaches her seventieth birthday, Oprah's primary focus is on maintaining her health and vitality, not just the numbers on the scale. She has emphasized that the medication is one tool in a regimen that includes rigorous exercise, structured meal times, hydration, and dietary principles. In a recent interview, she stressed that there's no shortcut: she hikes daily, counts Weight Watchers points, and drinks a gallon of water each day. Oprah encourages listeners to understand that obesity is a disease based in the brain, and that shame and blame are harmful and misguided. The backlash she faced for admitting she takes medication—some critics say it is the “easy way out”—reflects larger societal debates about medical interventions, with Oprah herself challenging that narrative by sharing her experience of hard work and self-acceptance.Medical experts interviewed in national outlets continue to say that GLP-1 drugs like Ozempic can help people lose between 15 to 20 percent of their body weight when paired with lifestyle changes like healthy eating and physical activity. They caution that success is not just about taking a weekly injection or pill but requires sustained adherence and behavioral support. Side effects like nausea, vomiting, and stomach pain remain a consideration, and patients are advised to consult closely with their health care providers.Meanwhile, innovation in obesity management is accelerating. The upcoming oral formulations of semaglutide and similar molecules could make therapy more accessible and acceptable to a wider population. However, newer approaches, like targeting metabolic pathways beyond appetite control, are on the horizon and may ultimately change how weight is managed over the long term.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Speculation is building on who'll be the next Governor of the Reserve Bank, and the Government is due to make an announcement tomorrow. A source has told Bloomberg the new Governor is a woman - and is from overseas. Speculation has centred on the Bank of England's Sarah Breerdon. Newstalk ZB reporter Azaria Howell speculates ahead of the big announcement. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Speculation is building on who'll be the next Governor of the Reserve Bank, and the Government is due to make an announcement tomorrow. A source has told Bloomberg the new Governor is a woman - and is from overseas. Speculation has centred on the Bank of England's Sarah Breerdon. Newstalk ZB reporter Azaria Howell speculates ahead of the big announcement. LISTEN ABOVESee omnystudio.com/listener for privacy information.

The new talk of bodybuilding, and the newest Tampa Pro & Texas Pro Champ.Timestamps:00:00:00 Jordan Hutchinson: Intro00:03:32 4 ½ Weeks Out from the Olympia00:07:08 Gyno Surgery Drama and Complications00:16:43 Low-Carb Days and Refeeds with Patrick Tour00:27:14 26-Week Prep Marathon Breakdown00:36:16 Branch Warren's Offseason Wisdom00:43:21 Growing on Low Food and Steps Focus00:50:36 Tournament of Champions Homecoming01:00:06 Classic vs Open: Weight Caps Exposed01:09:12 Neck-and-Neck with Urs at Olympia?01:16:46 Backing Off Quads to Boost Arms01:25:34 Division Switch Struggles01:32:49 P90X Sparks and Early Gains01:38:06 Beginnings01:47:11 Sugar Fairy Confessions01:52:22 Changes That Aided James's Progress01:55:15 Kratom Myths Busted02:01:39 Dropping from 700mg Tren to 260mg02:11:51 Faith's Role in Adversity02:16:39 Bodybuilding's Finance Reality02:18:58 Final Message: Find Your Purpose

Nicola Willis says there's been a clear message to all ministers - we don't want the billions recently allocated for infrastructure sitting in Government bank accounts. A small scale hospital project announcement yesterday and a school property maintenance announcement today have both talked up the boost they'll give the construction sector in the coming 12 months. The Finance Minister says they want signed contracts, spades in the ground, and jobs. "The instruction to all Government ministers has been - make sure you know where your maintenance contracts are at, where those construction projects are at, to get them out the door." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Wall Street trades at record highs after the Fed cut rates, led by technology stocks. Investors expect further cuts, but hawkish Fed comments pushed both US Treasury yields and the dollar higher last week. In Europe, data showed industrial output rebounding; in Asia, Bank of Japan's ETF unwind plans initially weighed on Japanese shares, but concerns are easing this Monday. Gold rises for a fifth week with record ETF inflows, Apple climbs after the iPhone 19 launch, and Porsche postpones its EV launch. Trump's USD 100,000 H-1B visa fee threatens US tech and India-US relations. Mensur Pocinci, Head of Technical Analysis, notes that strong US equities year-to-date and in September bode very well for the rest of the year.(00:00) - Introduction: Bernadette Anderko, Product & Investment Content (00:45) - Markets wrap-up: Mike Rauber, Product & Investment Content (06:47) - Technical Analysis update: Mensur Pocinci, Head of Technical Analysis (09:33) - Closing remarks: Bernadette Anderko, Product & Investment Content Would you like to support this show? Please leave us a review and star rating on Apple Podcasts, Spotify or wherever you get your podcasts.

Nicola Willis says there's been a clear message to all ministers - we don't want the billions recently allocated for infrastructure sitting in Government bank accounts. A small scale hospital project announcement yesterday and a school property maintenance announcement today have both talked up the boost they'll give the construction sector in the coming 12 months. The Finance Minister says they want signed contracts, spades in the ground, and jobs. "The instruction to all Government ministers has been - make sure you know where your maintenance contracts are at, where those construction projects are at, to get them out the door." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Robbie Campo, Campo's Marina, gives his field report

New Knights coach Justin Holbrook says he's looking forward to working with superstar captain Kalyn Ponga next year after meeting with him for the first time on Friday.See omnystudio.com/listener for privacy information.

Overseas markets and stocks are staging a comeback after nearly 20 years of trailing their U.S. counterparts. Artisan International Fund's award-winning Mark Yockey is finding undervalued growth stocks with plenty of room to run.WEALTHTRACK episode 2212, broadcast 09-19-25

Gio Reyna made his long-awaited Borussia Mönchengladbach debut, and it showed exactly why the USMNT need him at the 2026 World Cup. In this video, I break down Reyna's performance in detail, focusing on his decision-making, his “pass first, dribble second” style of play, and how he can continue to develop throughout the season.Alongside Reyna's debut, I also give a full American's Abroad update, including Tim Weah scoring at the Santiago Bernabéu against Real Madrid, Ricardo Pepi scoring a brace, and the latest performances from USMNT's stars making an impact across Europe.Follow Yanks Abroad Social Channels:TikTok - https://www.tiktok.com/@yanksabroadInstagram - https://www.instagram.com/yanksabroadpod/Twitter - https://twitter.com/yanksabroadpod#USMNT #Pochettino #ChristianPulisic #GioReyna #WorldCup #Soccer

Colorado real estate market opportunities are expanding as distressed builders offer properties at steep discounts. Atlas Real Estate VP Mike Hills manages 6,000+ doors across 10 states and reveals how current market conditions create exceptional opportunities for Colorado investors. These market opportunities include 15-25% discounts on builder inventory and multiple recovery signals indicating 2025 market conditions favor strategic investors.

Sign up for our Hormone Replacement Therapy Risk-Free Membership!https://www.alluremedical.com/hrt-membershipNew innovations have been discovered for the vitality of women in menopause.In this episode, Dr. Charles Mok talks about his book “Testosterone: Strong Enough For A Man, Made For A Woman,” and highlights the essential role of testosterone and hormone replacement therapy (HRT) in promoting healthy aging.He explores the benefits of HRT, shares insights into treatments and supplements that have supported women's intimate health over the years, and the use of platelet-rich fibrin (PRF) and hyaluronic acid as safe, sustainable approaches for sexual wellness and libido.Tune in to Inside The Cure Podcast — Promising Treatments for Women's Intimate HealthSubscribe to the podcast and leave a 5-star review!You can also catch this show on our YouTube channel and on all your favorite podcast platforms.Download Dr. Charles Mok's book, “Testosterone: Strong Enough for a Man, Made for a Woman” for free here. https://www.alluremedical.com/books/ Dr. Charles Mok received his medical degree from Chicago College of Osteopathic Medicine, Chicago, Illinois in 1989. He completed his medical residency at Mount Clemens General Hospital, Mt. Clemens, Michigan. He has worked with laser manufacturing companies to improve their technologies; he has performed clinical research studies and has taught physicians from numerous other states. His professionalism and personal attention to detail have contributed to the success of one of the first medical spas in Michigan.LinkedIn: https://www.linkedin.com/in/charles-mok-4a0432114/ Instagram: https://www.instagram.com/alluremedicals/ Website: https://www.alluremedical.com/ YouTube: https://www.youtube.com/@AllureMedical TikTok: https://www.tiktok.com/@alluremedical  Amazon Store: https://www.amazon.com/stores/Dr.-Charles-Mok/author/B0791M9FZQ?ref=ap_rdr&store_ref=ap_rdr&isDramIntegrated=true&shoppingPortalEnabled=true Join the Allure Medical Inner Circle Membership:https://www.alluremedical.com/inner-circle-membership/ 

Today, we have the next episode in our series of sponsored podcasts with highly vetted companies.  I am delighted to connect with Sarah Kennedy, the founder and CEO of Calocurb, a revolutionary product for weight management that became commercialized after 15 years and $30 million of research from the New Zealand government. Calocurb currently sells in five international markets and continues to grow rapidly through channels and geographies.  Sarah is a veterinarian by training and has held several senior executive positions in the agribusiness and food industries. In our conversation today, we explore the science behind Calocurb, the evolutionary mechanisms of satiety, and how Calocurb reduces caloric intake by 18%. We discuss endogenous GLP-1 drugs, highlighting how Calocurb's mechanism of action differs, and examining current research on gender differences in GLP-1 secretion, including their impact on the menstrual cycle and intermittent fasting. Sarah also covers the four core tenets of Calocurb, shares upcoming research that excites her, and explains the key differences between Calocurb and other supplements, like berberine and chromium. This conversation is truly invaluable, so it's worth revisiting. I am excited about Calocurb's potential to support a variety of needs, helping those looking to improve their hunger and satiety mechanisms, and assisting those taking GLP-1 medications who want to reduce their dosage and transition off GLP-1 medications without compromising the long-term results. IN THIS EPISODE, YOU WILL LEARN: How Calocurb began How Calocurb supports those on GLP-1s looking to lower their doses or taper off (in conjunction with their healthcare team) Sarah explains why Calocurb is very safe, and its four to six-hour mode of action.  The three primary use cases for Calocurb, and how it helps to reduce the side effects and costs associated with GLP-1 injections The importance of making lifestyle changes when transitioning off GLP-1 medications How Calocurb stimulates natural GLP-1 receptors, making it easier to manage food cravings during intermittent fasting Sarah shares how Calocurb helped her manage her love-hate relationship with food. How to take Calocurb for optimal effectiveness Sarah outlines Calocurb's four core values.  How Calocurb differs from other supplements Foods that help to reinforce the satiety mechanism Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Sarah Kennedy Calocurb  Research Articles: Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting  New Zealand Bitter Hops Extract Reduces Hunger During a 24h Water  Only Fast Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program   

2 Peter 2:2-22 | Pastor Rick In this Sunday Night in the Café message (2 Peter 2:11–22), Pastor Rick warns that false teachers often arise inside the church looking convincing but proving empty. Promising “freedom” while enslaved to corruption themselves. Using Peter's vivid images (wells without water, clouds without rain), he calls us to discernment: be people who measure every claim by Scripture, test the spirits, and watch for wolves in sheep's clothing. Stay close to Jesus and His Word, rely on the Holy Spirit for wisdom, refuse manipulative hype, and help new believers find solid ground in the truth. Packinghouse's Sunday evening worship service from September 14, 2025. - Rick Cornejo - Monday, September 15, 2025

2 Peter 2:2-22 | Pastor Rick In this Sunday Night in the Café message (2 Peter 2:11–22), Pastor Rick warns that false teachers often arise inside the church looking convincing but proving empty. Promising “freedom” while enslaved to corruption themselves. Using Peter's vivid images (wells without water, clouds without rain), he calls us to discernment: be people who measure every claim by Scripture, test the spirits, and watch for wolves in sheep's clothing. Stay close to Jesus and His Word, rely on the Holy Spirit for wisdom, refuse manipulative hype, and help new believers find solid ground in the truth. Packinghouse's Sunday evening worship service from September 14, 2025. - Rick Cornejo - Monday, September 15, 2025

The Auburn Tigers are off to a 3-0 start — but what does that really tell us? In this episode, we break down the early-season highs and lows. From standout performances on both sides of the ball to areas where Auburn still needs to tighten up, we're giving you a balanced look at what's working and what's still a work in progress. Are the Tigers contenders, or are there cracks beneath the surface? Let's talk about it. Learn more about your ad choices. Visit megaphone.fm/adchoices

Nearly 50,000 cases of the blood vessel cancer called canine hemangiosarcoma are diagnosed each…

Nearly 50,000 cases of the blood vessel cancer called canine hemangiosarcoma are diagnosed each year in the U.S. It's invariably fatal, although removing the dog's spleen and chemotherapy may extend...

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamabMonitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamigPresenters: Dr Christopher Flowers Division Head, Division of Cancer MedicineChair, Professor, Department of Lymphoma/MyelomaJohn Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer MedicineMD Anderson Cancer CenterHouston, TexasDr John AllanAssociate Professor of Clinical MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by Regeneron Pharmaceuticals, Inc.

The National Security Hour with Blanquita Cullum – Things are heating up in Chile as China eyes control of a new Pacific hub, COPIAPORT-E. Promising eco-friendly infrastructure, green energy, and massive shipping capacity, it raises sharp questions. Will Argentina, Brazil, and neighbors embrace it? Can the U.S. afford to stay sidelined as Beijing expands influence in South America's trade and security landscape?

Oracle's (ORCL) "cloud dreams came true, can the A.I. dream come true?" That's the question Dion Hinchcliffe poses after seeing Oracle's strong earnings and guidance that sent the stock soaring more than 40%. While the company has incredible growth aspirations, Dion says the issue Oracle faces will be reaching into "deep pockets" to ensure that guidance comes true. He notes positives that lay out a bullish road forward, including its cloud products and "diversified" business avenues.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

The National Security Hour with Blanquita Cullum – Things are heating up in Chile as China eyes control of a new Pacific hub, COPIAPORT-E. Promising eco-friendly infrastructure, green energy, and massive shipping capacity, it raises sharp questions. Will Argentina, Brazil, and neighbors embrace it? Can the U.S. afford to stay sidelined as Beijing expands influence in South America's trade and security landscape?

Hey my wonderful sweet babies, Follow Me:Instagram- fabvictoria94Twitter- VictoriaB_94Snapchat- fabvictoria94TikTok: FabVictoria94Facebook: Victoria BishopFacebook Page- Fabulous Victoria BroadcastsPatreon: Fabulous Victoria PodcastPodcast Name- Fabulous Victoria PodcastYouTube Main Channel: Fabulous VictoriaCashApp: $fabvictoria (optional)Music from Simply Kee Simone, Dessie Style, and Kaysie Amya on YouTube.Email me for business inquiries only:bishopvictoria94@gmail.comTHIS VIDEO IS NOT SPONSORED.

Bongani Bingwa speaks to Fatima Hassan, human rights lawyer and founder of the Health Justice Initiative, about the SA AIDS Conference currently underway with experts and delegates to confront South Africa’s HIV crisis head-on, examining both the progress made and the challenges that remain. While rising numbers reflect the ongoing spread of the virus, they also highlight the success of antiretroviral treatment in keeping millions alive who might otherwise have lost their lives. 702 Breakfast with Bongani Bingwa is broadcast on 702, a Johannesburg based talk radio station. Bongani makes sense of the news, interviews the key newsmakers of the day, and holds those in power to account on your behalf. The team bring you all you need to know to start your day Thank you for listening to a podcast from 702 Breakfast with Bongani Bingwa Listen live on Primedia+ weekdays from 06:00 and 09:00 (SA Time) to Breakfast with Bongani Bingwa broadcast on 702: https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/36edSLV or find all the catch-up podcasts here https://buff.ly/zEcM35T Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

The 2025 Low-Carbon Real Estate Exhibition brought together more than 12,500 professionals at the Grand Palais to tackle a common challenge: designing sustainable and desirable living spaces. In this new episode of Com d'Archi, we look back at this rapidly growing event, which enlightens architects on concrete solutions for low-carbon construction.This 4th edition of SIBCA has established itself as a showcase for architectural and construction innovations that support the ecological transition. Wood, recycled aluminum, bio-based or reused materials, health and quality of life as design drivers: the avenues are diversifying and becoming more refined. Architects, developers, engineers, designers, and manufacturers presented their advances and compared their visions in a fruitful dialogue that went beyond the field of real estate alone.From Redman to Care Promotion, SOPREMA to Sybois or CoolRoof, Vitra to inventive start-ups such as Anga, Ostrea, and Le Pavé, the ecosystem revealed its dynamism. The importance given to heritage, with the Grand Palais as a backdrop, also served as a reminder that decarbonization applies at all levels, from historic monuments to new neighborhoods.Despite political turmoil, the sector is proving its ability to mobilize creativity and collective intelligence. For architects, this trade show offers a compendium of inspiring practices and potential partners, all of which are resources for designing resilient, low-carbon spaces that are rich in quality of use. It is an event that confirms that architecture is at the heart of building a desirable future.__This English version was generated using AI with voice cloning, preserving the speaker' timbre and the natural French accent. We are currently testing this technology. Please excuse any imperfections. We are working to improve this system so that we can expand our broadcasts to multiple languages. But our favorite Esther will be back soon in English!Speakers : Anne-Charlotte Depondt Audio production comdarchipodcastImage teaser © Anne-Charlotte Depondt ___If you like the podcast do not hesitate:. to subscribe so you don't miss the next episodes,. to leave us stars and a comment :-),. to follow us on Instagram @comdarchipodcast to find beautiful images, always chosen with care, so as to enrich your view on the subject.Nice week to all of you ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Let us help you find YOUR home in Portugal...Whether you are looking to BUY, RENT or SCOUT, reach out to Carl Munson and connect with the biggest and best network of professionals that have come together through Good Morning Portugal! over the last five years that have seen Portugal's meteoric rise in popularity.Simply contact Carl by phone/WhatsApp on (00 351) 913 590 303, email carl@carlmunson.com or enter your detailsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-good-morning-portugal-podcast-with-carl-munson--2903992/support.Let us help you find YOUR home in Portugal...Whether you are looking to BUY, RENT or SCOUT, reach out to Carl Munson and connect with the biggest and best network of professionals that have come together through Good Morning Portugal! over the last five years that have seen Portugal's meteoric rise in popularity.Simply contact Carl by phone/WhatsApp on (00 351) 913 590 303, email carl@carlmunson.com or enter your details

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Promising rate-cut expectations pushed Wall Street to fresh record highs, as weaker jobs data, including softer private payrolls, fueled hopes of the Federal Reserve easing and sent US bond yields lower. In company news, Broadcom delivered an upbeat forecast on strong AI demand. In commodities, oil prices eased as OPEC considered a potential output hike, while iron ore climbed to multi-week highs on hopes of improving Chinese demand. Back home, Australian shares are expected to open higher on Friday. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

While the Roadrunners weren't able to pull the upset against #19 Texas A&M, UTSA sure looked the part against an SEC foe. Winning in the trenches and mostly avoiding penalties, Jeff Traylor feels like his team has the right stuff to compete for a championship. UTSA will have a chance to prove their progression over the offseason this week as they welcome Texas State to the Alamodome for the home opener. Can UTSA avenge last year's awful loss in the I-35 Showdown? 04:20 A&M performance recap 34:08 Listener voicemails 46:03 Previewing the Texas State Bobcats 1:11:00 Score predictions Video: https://youtu.be/9MGWFtoFNK0 Learn more about your ad choices. Visit megaphone.fm/adchoices

While the Roadrunners weren't able to pull the upset against #19 Texas A&M, UTSA sure looked the part against an SEC foe. Winning in the trenches and mostly avoiding penalties, Jeff Traylor feels like his team has the right stuff to compete for a championship. UTSA will have a chance to prove their progression over the offseason this week as they welcome Texas State to the Alamodome for the home opener. Can UTSA avenge last year's awful loss in the I-35 Showdown? 04:20 A&M performance recap 34:08 Listener voicemails 46:03 Previewing the Texas State Bobcats 1:11:00 Score predictions Video: https://youtu.be/9MGWFtoFNK0

This week, LevelCap and Matimi0 discuss the latest round of Battlefield 6 leaks, China's big gamble on game development, the awesome update for Helldivers 2, and much more! Support us on Patreon for bonus content!  https://www.patreon.com/LevelWithMePodcast Join Our Discord and make suggestions for our next episode topics  https://discord.gg/nxBQZ6eh8H

In this episode, host Jonathan Sackier is joined by Andrew Dunbar, Assistant Professor in the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center, Houston, USA. Dunbar discusses his research into myeloproliferative neoplasms, what drives disease progression and resistance, and promising targets for treatment, while reflecting on the mission of his lab and what lies ahead for the field.  Timestamps  00:00 – Introduction  02:29 – One thing people should know about myeloproliferative neoplasms  05:01 – Dunbar's background and research focus  08:00 – What would Dunbar do if not science and medicine?  10:24 – The basics of myeloproliferative neoplasms  14:30 – Myeloproliferative neoplasm diagnosis and treatment  16:49 – What drives disease progression and resistance?  18:30 – The mission of Dunbar's lab  21:23 – Development of AJ1-11095  22:54 – Balancing the complexity of disease modelling with urgent clinical needs  24:03 – Promising targets and pathways  26:35 – What's on the horizon?  28:40 – Three wishes 

Chicago Bulls Eye Malik Beasley As Promising Addition, Enhancing Roster Potential by Jaggy Sports

Katrina is on a role in this short episode as she discusses the broken model of the "one-hour prophy". Listen as she discusses the dangers of blindly following this model and gives 5 ways to improve the appointments.  Resources: More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/ Katrina Sanders Website: https://www.katrinasanders.com  Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/ 

On today's podcast, Charlie discusses the Green Bay Packers getting Micah Parsons, the Wisconsin Badgers' start, and the Milwaukee Brewers' World Series preview with the Toronto Blue Jays Charlie starts the show discussing the Packers going all-in to get Micah Parsons. The impact that he brings to the defense. What it does for the Packers in the NFC. Why the Packers did it now plus what happens if it goes south. From there, Charlie touches on the Wisconsin Badgers' shutout victory over Miami (OH) and why he saw some promise. Lastly, he talks about what might be a World Series preview series with the Milwaukee Brewers and Toronto Blue Jays

The team discusses 2025 Impeccable Baseball and 2024-25 Panini Silhouette Basketball. 

You keep making plans. Telling yourself this week will be different. Promising your chair, your friends, and yourself that you're going to finish this draft. But somehow the days go by and nothing gets done. In this episode, Dr. Marvette Lacy breaks down the real reason behind the cycle of avoidance and broken promises. It's not laziness. It's not a lack of time. It's the deep hit your confidence has taken and the fear that your best might not be good enough. If you're tired of feeling like a disappointment and ready to finally trust yourself again, this episode will show you how to rebuild belief, reset your plan, and take your next step forward.   Dissertation Information Qual Scholars Community: https://qual-scholars.circle.so/ 10 Pages In 2 Days Writing Retreat: https://qualscholars.com/10pages/ The Finish Your Dissertation Institute: https://qualscholars.com/theinstitute/  Qual Scholars Website: https://qualscholars.com/  Qual Scholars' Instagram: https://instagram.com/qual_scholars/

Alzheimer's disease is not a normal part of aging—and new research is showing how lifestyle, diet, and exercise may help prevent or delay cognitive decline. Want to learn more? Then please click on the podcast as two of Montana’s leading […] The post New Research is Promising in Battling Dementia/Alzheimer's first appeared on Voices of Montana.

In this week's episode of Your Drone Questions. Answered, host Chris Breedlove sits down with Benton Szejk from Wingtra to talk about where the drone industry is headed.With all the uncertainty around regulations, supply chains, tariffs, and evolving executive orders, many drone pilots and professionals are wondering: what's next? Benton shares insights from the manufacturer's perspective on:-The impact of the Blue and Green lists for drone certification-Supply chain challenges and how Wingtra is preparing for the future-Recent executive orders and what they mean for UAS policy in the U.S.-Key features needed for BVLOS operations-Wingtra's latest technology, including obstacle avoidance, LTE connectivity, and AI-powered tools-How drones are being used for mapping, surveying, environmental monitoring, and even public safetyWhether you're a drone operator, educator, or just passionate about the future of UAS, this episode offers encouragement and practical insights into what's ahead for the industry.https://wingtra.comhttps://wingtra.com/ray/ https://info.duncan-parnell.com/acton/media/23538/WingtraRAY-Roadshow

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Eric Verdin is a physician-scientist and the CEO of the Buck Institute for Research on Aging whose career has centered on understanding how epigenetics, metabolism, and the immune system influence the aging process. In this episode, Eric traces his scientific journey from studying viruses and histone deacetylases (HDACs) to leading aging research at the Buck Institute, offering insights into how aging impairs immune and nervous system function—including thymic shrinkage, chronic inflammation, and reduced vaccine response—and how these changes impact lifespan. He explores the metabolic underpinnings of aging, such as oxidative stress and insulin and IGF-1 signaling, and he discusses practical tools like zone 2 cardio, ketogenic diets, and GLP-1 drugs. The conversation also covers declining NAD levels with age, the roles of NAD-consuming enzymes such as sirtuins and CD38, and what current NAD-boosting strategies (like NMN, NR, and IV NAD) can and can't accomplish. Eric weighs in on promising longevity interventions including rapamycin, growth hormone for thymic regeneration, and anti-inflammatory therapies, while also examining the promise and limitations of current biological age tests and the potential of combining epigenetic, proteomic, and organ-specific metrics with wearables to guide personalized longevity care. We discuss: Eric's scientific journey from virology to the field of geroscience [2:45]; How dysfunction in the immune system and central nervous system can drive aging throughout the body [5:00]; The role of metabolism and oxidative stress in aging, and why antioxidant strategies have failed to deliver clear benefits [8:45]; Other aspects of metabolism linked to aging: mitochondrial efficiency, fuel utilization, and glucose-modulating drugs [16:30]; How inefficient glucose metabolism drives insulin, IGF-1 signaling, and accelerates aging [21:45]; The metabolic effects of GLP-1 agonists, and the need to move beyond crude metrics like BMI in favor of more precise assessments of metabolic health [27:00]; The case for immune health as a “fifth horseman” [36:00]; How the innate and adaptive immune systems work together to build immune memory [39:45]; Why vaccines lose effectiveness with age: shrinking of the thymus gland and diminished T-cell diversity [44:15]; Exploring growth hormone, thymic regeneration, and the role of exercise in slowing immune aging [48:45]; The challenges of identifying reliable biomarkers for immune function, and the potential of rapamycin analogs to enhance vaccine response in older adults [57:45]; How rapamycin's effects on the immune system vary dramatically by dosage and frequency [1:03:30]; The limitations of mouse models in aging research and the need for cautious interpretation of rapamycin's benefits in humans [1:08:15]; NAD, sirtuins, and aging: scientific promise amid commercial hype [1:15:45]; How CD38 drives age-related NAD decline, influences immune function, and may impact longevity [1:23:45]; How NMN and NR supplementation interact with CD38 and NAD metabolism, and potential risks like homocysteine elevation and one-carbon cycle depletion [1:31:00]; Intravenous NAD: limited evidence and serious risks [1:37:00]; Interleukin-11 (IL-11) as a new target in immune aging, the dual role of chronic inflammation in aging, and the need for better biomarkers to guide interventions [1:43:00]; Biological aging clocks: types of clocks, promise, major limitations, and future outlook [1:48:30]; The potential of proteomics-based aging clocks for detecting organ-specific decline and frailty [2:00:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube